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Background: Osteopontin (OPN) plays a critical role in cell proliferation and drug resistance in cancer treatment and hematological 
malignancies. In T cell acute lymphoblastic leukemia, most initial therapies can induce remission while some patients then relapse 
and do not respond well to chemotherapy. The sesquiterpene lactone parthenolide (PTL) can induce apoptosis in a variety of can-
cer cell lines via inhibition of pro-inflammatory transcription factor nuclear factor kappa B and has anti-tumor activity in acute 
lymphoblastic leukemia treatment. Aim: To study the role of OPN in conferring in vitro resistance to PTL in Jurkat cells. Methods: 
Jurkat cells were cultured with 8–20 μm PTL for 48 h. Transfection with OPN siRNA was provided. Apoptosis assays were per-
formed with Annexin V-Alexa Fluor-488/PI. Quantitative real-time polymerase chain reaction was used to measure OPN gene 
expression using the 2-2-ΔΔCt method. Results: PTL has cytotoxic and apoptotic effect on Jurkat cells with IC50 values of 16.1 μm, 
and growth inhibition effect of PTL does not differ significantly in combination with OPN-siRNA. OPN gene expression is not 
affected by PTL. Conclusions: Parthenolide induces apoptosis in Jurkat cells, but inhibition of osteopontin gene expression with 
siRNA does not reduce apoptotic effect of parthenolide.
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Osteopontin (OPN), also known as secreted phos-
phoprotein 1 is a 34kD multidomain secreted glyco-
protein that functions as a soluble cytokine and an ad-
hesive component of the extracellular matrix [1, 2]. 
It is a member of small integrin-binding ligand N-linked 
glycoproteins (siblings), a family of five integrin binding 
glycophosphoproteins [3]. OPN interacts mainly with 
various αv (particularly αvβ1, αvβ3, αvβ5) integrins and 
with the CD44 splice variants. Due to these properties, 
OPN induces the activation of signal transduction path-
ways leading to cell proliferation, adhesion, invasion 
and migration. Hence, its role in cancer is important, 
as it is involved in angiogenesis, and metastasis [4–7]. 
OPN, also called early T cell activation gene 1 (Eta-1), 
is expressed after activation of T cells, macrophages 
and in multiple tissue types. OPN is cleaved by some 
proteases such as thrombin, cleaved product par-
ticipating in various cellular functions. Jurkat cells 
originating from T cell acute lymphoblastic leukemia 
(T-ALL) have enhanced cell adhesion to thrombin-
cleaved OPN compared with full-length OPN [8, 9].
Given that the human OPN gene is encoded 
by a single-copy gene on chromosome 4q21-q25 and 
has an alternative translation start site, there are two 
major variants of OPN, intracellular and extracellu-
lar [1]. It is also subjected to alternative splicing as well 
as post-translational modifications such as phos-
phorylation, glycosylation and proteolytic cleavage.
Parthenolide (PTL)-containing herbs are highly 
bioactive and have been traditionally used for treat-
ment of inflammations. The anti-inflammatory activi-
ties of these herbs are partially due to their anti-NF-
kB effects [10]. Currently PTL is used extensively 
in cancer treatment [11–14]. It can induce oxidative-
stress-mediated apoptosis in T cells at high doses 
(up to 10 µm) [15].
T-ALL represents approximately 12% to 15% of all 
newly diagnosed acute lymphocytic leukemia (ALL) 
cases in pediatric patients and about 25% of adult 
ALL. This aggressive malignancy is associated with 
a significant risk of disease relapse and does not re-
spond well to chemotherapy [16–18].
Herein, we attempted to study the role of OPN 
in conferring in vitro resistance to PTL in Jurkat cells 
and to examine the effect of knockdown of OPN gene 
expression via OPN-siRNA on PTL-treated Jurkat cell 
survival.
MATERIALS AND METHODS
Reagents. Parthenolide was purchased from Sig-
ma-Aldrich (USA) and dissolved in dimethyl sulfoxide 
(DMSO) as a 50 mM stock solution, stored at –20 °C, 
and diluted in DMSO before use. The Annexin V-FITC/
PI kit was purchased from BD Biosciences (USA). 
Tripure Isolation Reagent was purchased from Roche 
Applied Science (Germany). The cDNA synthesis kit 
and SYBR® Premix Ex Taq™ were purchased from Ta-
kara Biotechnology Co. (Otsu, Japan).
Cell culture. The human leukemic Jurkat cell line 
was obtained from the Iranian Biological Resource 
Center. RPMI 1640 supplemented with 10% fetal 
bovine serum medium (Invitrogen, USA) was used 
for culturing. The medium was supplemented with 
2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/
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